.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A randomized controlled trial tested a brief motivational-enhancement education program for people starting CPAP therapy for obstructive sleep apnea. The intervention combined a short educational video, a patient-centered interview and telephone follow-up, with an emphasis on improving knowledge, motivation and self-efficacy. Compared with usual care, participants receiving the intervention used CPAP substantially more and were more likely to meet a commonly used adherence threshold. Daytime sleepiness and treatment self-efficacy also improved. The paper is useful because it translates the abstract idea of “counselling” into a concrete behavioral intervention that can be delivered around the time CPAP is initiated. The results support early, structured engagement rather than assuming that patients will naturally adapt to a new device. In the NAPCON context, this complements the conference focus on counselling, adherence and diagnosis gaps in OSA. The trial also highlights an important caveat: it was a relatively small study with short follow-up, so the sustainability of the effect over years remains less certain. Still, the findings provide a practical evidence base for incorporating motivational and patient-centered support into CPAP initiation.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A randomized controlled trial tested a brief motivational-enhancement education program for people starting CPAP therapy for obstructive sleep apnea. The intervention combined a short educational video, a patient-centered interview and telephone follow-up, with an emphasis on improving knowledge, motivation and self-efficacy. Compared with usual care, participants receiving the intervention used CPAP substantially more and were more likely to meet a commonly used adherence threshold. Daytime sleepiness and treatment self-efficacy also improved. The paper is useful because it translates the abstract idea of “counselling” into a concrete behavioral intervention that can be delivered around the time CPAP is initiated. The results support early, structured engagement rather than assuming that patients will naturally adapt to a new device. In the NAPCON context, this complements the conference focus on counselling, adherence and diagnosis gaps in OSA. The trial also highlights an important caveat: it was a relatively small study with short follow-up, so the sustainability of the effect over years remains less certain. Still, the findings provide a practical evidence base for incorporating motivational and patient-centered support into CPAP initiation.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
